{"id":806124,"date":"2026-05-01T10:25:02","date_gmt":"2026-05-01T10:25:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=806124"},"modified":"2026-05-01T10:25:02","modified_gmt":"2026-05-01T10:25:02","slug":"inflammatory-bowel-disease-market-growth-momentum-across-7mm-to-2034-delveinsight-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead-galapagos-applied-moleculara","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/inflammatory-bowel-disease-market-growth-momentum-across-7mm-to-2034-delveinsight-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead-galapagos-applied-moleculara_806124.html","title":{"rendered":"Inflammatory Bowel Disease Market: Growth Momentum Across 7MM to 2034 \u2013 DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly and Company, Gilead, Galapagos, Applied Moleculara"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777569233.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Inflammatory Bowel Disease Market: Growth Momentum Across 7MM to 2034 &ndash; DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly and Company, Gilead, Galapagos, Applied Moleculara\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777569233.jpg\" alt=\"Inflammatory Bowel Disease Market: Growth Momentum Across 7MM to 2034 &ndash; DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly and Company, Gilead, Galapagos, Applied Moleculara\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Inflammatory Bowel Disease Companies in the market include &#8211; AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience\/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s report, <strong>&ldquo;Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2034&rdquo;<\/strong> provides a comprehensive analysis of the Inflammatory Bowel Disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Additionally, it examines Inflammatory Bowel Disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/inflammatory-bowel-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Inflammatory Bowel Disease Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Inflammatory Bowel Disease Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Inflammatory Bowel Disease market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2020-2034).<\/p>\n<\/li>\n<li>\n<p><strong>In February 2026, ABVX \/ Nasdaq: ABVX),<\/strong> a clinical-stage biotech company developing therapies that leverage the body&rsquo;s natural regulatory pathways to maintain immune balance in chronic inflammatory conditions, has announced new preclinical and clinical findings for obefazimod. The data were presented at the European Crohn&rsquo;s and Colitis Organisation Annual Congress. These results strengthen the evidence supporting obefazimod&rsquo;s development in Inflammatory bowel disease, showcasing its anti-fibrotic effects in Crohn&rsquo;s disease, along with a favorable safety and tolerability profile, rapid symptom relief, and further validation of its mechanism of action through upregulation of the miR-124 to restore immune homeostasis.<\/p>\n<\/li>\n<li>\n<p>In 2023, the United States had the largest number of cases among the 7MM, with approximately 14 million prevalent cases. These numbers are anticipated to rise in the forecast period.<\/p>\n<\/li>\n<li>\n<p>In the United States in 2023, irritable bowel syndrome was more prevalent among females than males in terms of total gender-specific cases.<\/p>\n<\/li>\n<li>\n<p>In 2023, Germany had the highest prevalence of irritable bowel syndrome among the EU4 and the UK, whereas Spain reported the lowest number of cases.<\/p>\n<\/li>\n<li>\n<p>According to Breen-Lyles et al. (2023), the average symptom severity score of irritable bowel syndrome in patients meeting Rome IV criteria was notably higher compared to those meeting Rome III criteria.<\/p>\n<\/li>\n<li>\n<p>According to the American College of Gastroenterology (2023), irritable bowel syndrome is prevalent, impacting approximately 5% of the population, which equates to about 1 in 20 individuals in the US.<\/p>\n<\/li>\n<li>\n<p><strong>Key Inflammatory Bowel Disease Companies:<\/strong> AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience\/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A\/S, 4SC AG, Pharmacosmos A\/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Inflammatory Bowel Disease Therapies:<\/strong> RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others<\/p>\n<\/li>\n<li>\n<p>The Inflammatory Bowel Disease market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Irritable Bowel Syndrome (IBS) is a common disorder that affects the large intestine (colon). It is characterized by a group of symptoms that occur together, including abdominal pain or discomfort, bloating, and changes in bowel habits such as diarrhea, constipation, or both. IBS is a chronic condition that can vary in severity and typically requires long-term management.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Inflammatory Bowel Disease Market Report:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-bowel-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/inflammatory-bowel-disease-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The Inflammatory Bowel Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Age-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Severity-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Subtype-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of Irritable Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/inflammatory-bowel-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Inflammatory Bowel Disease Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Recent Development In The Inflammatory Bowel Disease Treatment Landscape:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>In May 2025, ALPCO introduced its Calprotectin Immunoturbidimetric Assay in Europe<\/strong> to aid in diagnosing inflammatory bowel disease (IBD), such as Crohn&rsquo;s disease and ulcerative colitis. The assay, already FDA-cleared and IVDD-certified, is designed to help differentiate IBD from irritable bowel syndrome (IBS) when combined with other clinical information.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, Eli Lilly and Company<\/strong> reported that the U.S. Food and Drug Administration (FDA) has granted approval to Omvoh&reg; (mirikizumab-mrkz) for adults with moderately to severely active Crohn&rsquo;s disease. With this approval, Omvoh is now authorized in the U.S. for two inflammatory bowel diseases (IBD), following its October 2023 approval as the first-in-class therapy for moderately to severely active ulcerative colitis (UC) in adults.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>RINVOQ (upadacitinib): AbbVie<\/p>\n<\/li>\n<li>\n<p>STELARA (ustekinumab): Janssen Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Obefazimod: Abivax<\/p>\n<\/li>\n<li>\n<p>MORF-057: Morphic Therapeutic<\/p>\n<\/li>\n<li>\n<p>Blautix: CJ Bioscience\/4D Pharma<\/p>\n<\/li>\n<li>\n<p>BEKINDA (RHB-102): RedHill Biopharma<\/p>\n<\/li>\n<li>\n<p>TRP-8802: Tryp Therapeutics<\/p>\n<\/li>\n<li>\n<p>Mirikizumab: Eli Lilly and Company<\/p>\n<\/li>\n<li>\n<p>Filgotinib: Gilead\/ Galapagos<\/p>\n<\/li>\n<li>\n<p>AMT-101: Applied Molecular Transport<\/p>\n<\/li>\n<li>\n<p>PN-943: Protagonist Therapeutics<\/p>\n<\/li>\n<li>\n<p>Tremfya: Janssen<\/p>\n<\/li>\n<li>\n<p>Brazikumab: AstraZeneca<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/inflammatory-bowel-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Inflammatory Bowel Disease Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rising global prevalence of IBD: Increasing incidence of Crohn&rsquo;s disease and ulcerative colitis, particularly in developed and emerging markets, is expanding the treated patient pool.<\/p>\n<\/li>\n<li>\n<p>Strong adoption of biologics and advanced therapies: TNF inhibitors, IL-12\/23 and IL-23 inhibitors, integrin blockers, and JAK inhibitors are driving market growth in moderate-to-severe disease.<\/p>\n<\/li>\n<li>\n<p>Shift toward early and aggressive treatment strategies: Earlier use of targeted therapies to prevent disease progression and complications is supporting higher treatment uptake.<\/p>\n<\/li>\n<li>\n<p>Robust clinical pipeline and innovation: Continued development of next-generation biologics, oral small molecules, and novel mechanisms is sustaining long-term market expansion.<\/p>\n<\/li>\n<li>\n<p>Improved diagnosis and disease awareness: Advances in endoscopy, imaging, biomarkers, and patient awareness are enabling earlier diagnosis and treatment initiation.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Inflammatory Bowel Disease Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>High cost of biologic therapies: Premium pricing of branded biologics and advanced therapies creates reimbursement challenges and limits access in cost-sensitive markets.<\/p>\n<\/li>\n<li>\n<p>Safety and tolerability concerns: Risks such as infections, malignancies, and long-term immunosuppression may restrict widespread or prolonged use.<\/p>\n<\/li>\n<li>\n<p>Loss of response and treatment resistance: Primary non-response and secondary loss of efficacy remain significant challenges in long-term disease management.<\/p>\n<\/li>\n<li>\n<p>Intense market competition: Crowded therapeutic classes and biosimilar entry are increasing pricing pressure and complicating differentiation.<\/p>\n<\/li>\n<li>\n<p>Complex treatment pathways and patient heterogeneity: Variable disease presentation and response make optimal therapy selection challenging, slowing treatment optimization.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Inflammatory Bowel Disease Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2020&ndash;2034<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Inflammatory Bowel Disease Companies:<\/strong> AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience\/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A\/S, 4SC AG, Pharmacosmos A\/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Inflammatory Bowel Disease Therapies:<\/strong> RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others<\/p>\n<\/li>\n<li>\n<p><strong>Inflammatory Bowel Disease Therapeutic Assessment:<\/strong> Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Inflammatory Bowel Disease Market Dynamics:<\/strong> Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Inflammatory Bowel Disease Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Inflammatory Bowel Disease Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/inflammatory-bowel-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Inflammatory Bowel Disease Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Inflammatory Bowel Disease<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Inflammatory Bowel Disease<\/p>\n<p style=\"text-align: justify;\">4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Inflammatory Bowel Disease Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Inflammatory Bowel Disease Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Inflammatory Bowel Disease Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Inflammatory Bowel Disease<\/p>\n<p style=\"text-align: justify;\">9. Inflammatory Bowel Disease Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Inflammatory Bowel Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Inflammatory Bowel Disease Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Inflammatory Bowel Disease Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Inflammatory Bowel Disease Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify;\">14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Inflammatory Bowel Disease Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Inflammatory Bowel Disease Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Inflammatory Bowel Disease Appendix<\/p>\n<p style=\"text-align: justify;\">18. Inflammatory Bowel Disease Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=inflammatory-bowel-disease-market-growth-momentum-across-7mm-to-2034-delveinsight-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead-galapagos-applied-moleculara\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=inflammatory-bowel-disease-market-growth-momentum-across-7mm-to-2034-delveinsight-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead-galapagos-applied-moleculara\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Inflammatory Bowel Disease Companies in the market include &#8211; AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience\/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Vifor Pharma, Astellas &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/inflammatory-bowel-disease-market-growth-momentum-across-7mm-to-2034-delveinsight-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead-galapagos-applied-moleculara_806124.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-806124","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=806124"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=806124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=806124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=806124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}